Pfizer says COVID-19 booster shot is promising against Omicron variant

pharmafile | December 9, 2021 | News story | |   

The companies said that the three doses provide a similar level of antibodies against Omicron, compared to that of two doses against other variants.

A WHO official has said that existing vaccines should still protect people who contract the Omicron variant from severe COVID-19 cases. Scientists believe that previous infection, followed by vaccination or a booster, will play a significant role in increasing the neutralisation level, and therefore will likely protect people against instances of severe disease. This provides further evidence for the efficacy of vaccines.

In a recent statement, Pfizer chief executive, Albert Bourla, said that protection against Omicron would be improved with a third dose of the jab. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster, remains the best course of action to prevent the spread of COVID-19,” he commented.

Pfizer and BioNTech are currently developing  an Omicron-specific vaccine, which will be ready for delivery within 100 days, pending regulatory approval.

There is not currently enough data yet on the efficacy of the Moderna, J&J, and other jabs, against Omicron. The recent variant was first identified in South Africa, which is currently experiencing a surge in COVID-19 reinfections.

Researchers across the world are working to piece together further data on Omicron.

Lina Adams

Related Content

No items found

Latest content